William Benton Jones Buys 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) insider William Benton Jones acquired 20,000 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average price of $1.73 per share, with a total value of $34,600.00. Following the completion of the acquisition, the insider now directly owns 153,773 shares of the company’s stock, valued at approximately $266,027.29. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Corvus Pharmaceuticals Price Performance

CRVS opened at $1.96 on Thursday. Corvus Pharmaceuticals, Inc. has a one year low of $1.05 and a one year high of $4.19. The company’s 50 day simple moving average is $1.77 and its 200-day simple moving average is $1.78. The stock has a market capitalization of $96.12 million, a P/E ratio of -3.77 and a beta of 1.05.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Tuesday, March 19th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). As a group, analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.47 EPS for the current year.

Institutional Investors Weigh In On Corvus Pharmaceuticals

An institutional investor recently raised its position in Corvus Pharmaceuticals stock. Towerview LLC increased its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 27.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 436,873 shares of the company’s stock after acquiring an additional 94,395 shares during the period. Corvus Pharmaceuticals comprises about 0.5% of Towerview LLC’s portfolio, making the stock its 17th largest position. Towerview LLC owned about 0.89% of Corvus Pharmaceuticals worth $769,000 as of its most recent filing with the Securities & Exchange Commission. 46.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CRVS shares. Cantor Fitzgerald restated an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Monday, April 1st. Oppenheimer upped their price objective on shares of Corvus Pharmaceuticals from $7.00 to $8.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Mizuho reissued a “neutral” rating and issued a $3.50 price target on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 27th.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.